The pandemic provided a reason to the stock market to be excited about the pharma sector that had been facing lacklustre prospects amid challenges in the US business, USFDA compliance issues, pricing pressure, big-bang acquisitions not working out on expected lines and modest growth in the domestic market.
Amish Shah turns bullish on pharma, remains cautious on IT
Indian equities are poised for a constructive phase, with strategists anticipating earnings acceleration and a potential revival in foreign investor interest. While near-term earnings surprises
December 15, 2025